DCOY

+ Watchlist + Portfolio

Decoy Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.41
52-Week Range: $3.28 – $75.36
Market Cap: $2.15M
P/E (TTM): 0.03
EPS (TTM): 115.98
Dividend Yield: —

Advanced Metrics

Price/Book: 0.30
PEG Ratio: —
Return on Equity: -827.77%
Return on Assets: -73.35%
Gross Margin: 0.00%
Operating Margin: -1055.84%
Profit Margin: 0.00%
Current Ratio: 1.83
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-509.88K
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-6.05M

DCOY Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$15.84M	$7.17M	$770.03K	$8.89M
Selling, General & Admin	$7.14M	$5.72M	$4.96M	$3.73M
Operating Expenses	$22.98M	$12.89M	$5.73M	$12.61M
Operating Income	-$22.98M	-$12.89M	-$5.73M	-$12.61M
EBITDA	-$22.97M	-$12.88M	-$5.73M	-$12.61M
Pretax Income	-$31.61M	-$12.54M	-$5.58M	-$12.52M
Net Income	-$31.61M	-$12.54M	-$5.58M	-$12.52M
Diluted EPS	-21427.20	-5533.20	-1043.10	-129.10
Diluted Shares	1475	2267	5345	96966

DCOY Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$12.11M	$5.90M	$2.43M	$10.71M
Receivables	$1.61M	$0.00	—	—
Current Assets	$14.52M	$6.52M	$2.99M	$10.99M
Total Assets	$14.65M	$6.59M	$3.02M	$11.06M
Current Liabilities	$4.27M	$1.30M	$1.51M	$5.17M
Total Debt	—	$289.64K	$221.87K	—
Total Liabilities	$4.27M	$1.30M	$1.51M	$5.17M
Retained Earnings	-$63.81M	-$76.35M	-$81.92M	-$94.44M
Shareholders' Equity	$10.38M	$5.29M	$1.51M	$5.89M
Working Capital	$10.25M	$5.22M	$1.48M	$5.82M

DCOY Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.60M	-$12.85M	-$4.53M	-$4.83M
Capital Expenditure	-$1.50M	—	—	-$577.00K
Free Cash Flow	-$19.10M	-$12.85M	-$4.53M	-$5.40M
Depreciation & Amortisation	$6.68K	$10.05K	$4.42K	$7.15K
Stock-Based Compensation	$796.80K	$524.84K	$273.73K	$219.06K
Investing Cash Flow	-$1.50M	$0.00	$0.00	$764.74K
Financing Cash Flow	$1.99M	$6.64M	$1.06M	$12.34M
Net Change in Cash	-$17.11M	-$6.21M	-$3.47M	$8.28M

DCOY Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$75.53K	$116.38K	$61.83K	$8.63M	$749.81K
Selling, General & Admin	$1.64M	$849.18K	$833.30K	$402.17K	$1.53M
Operating Expenses	$1.72M	$965.57K	$895.13K	$9.03M	$2.28M
Operating Income	-$1.72M	-$965.57K	-$895.13K	-$9.03M	-$2.28M
EBITDA	-$1.72M	-$964.46K	-$894.02K	-$9.03M	-$2.28M
Pretax Income	-$1.71M	-$957.83K	-$873.47K	-$8.98M	-$2.22M
Net Income	-$1.71M	-$957.83K	-$873.47K	-$8.98M	-$2.22M
Diluted EPS	-240.07	-81.00	-21.72	—	-4.18
Diluted Shares	7121	11793	40132	—	531968

DCOY Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.80M	$794.89K	$4.81M	$10.71M	$7.82M
Receivables	—	—	$200.00K	—	—
Current Assets	$2.31M	$1.36M	$6.06M	$10.99M	$8.36M
Total Assets	$2.34M	$1.39M	$6.10M	$11.06M	$8.42M
Current Liabilities	$2.28M	$2.22M	$1.85M	$5.17M	$4.55M
Total Debt	$112.23K	—	—	—	—
Total Liabilities	$2.28M	$2.22M	$1.85M	$5.17M	$4.55M
Retained Earnings	-$83.63M	-$84.59M	-$85.46M	-$94.44M	-$96.67M
Shareholders' Equity	$61.87K	-$829.72K	$4.25M	$5.89M	$3.88M
Working Capital	$27.56K	-$862.92K	$4.22M	$5.82M	$3.81M

DCOY Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.18M	-$862.30K	-$1.65M	-$1.14M	-$2.89M
Free Cash Flow	-$1.18M	-$862.30K	-$1.65M	-$1.71M	-$2.89M
Depreciation & Amortisation	$1.11K	$1.11K	$1.11K	$3.83K	$5.92K
Stock-Based Compensation	$33.53K	$23.16K	$22.85K	$139.52K	$213.04K
Investing Cash Flow	—	—	—	$964.74K	—
Financing Cash Flow	$545.57K	-$141.20K	$5.86M	$6.07M	$0.00
Net Change in Cash	-$636.15K	-$1.00M	$4.01M	$5.90M	-$2.89M

Market Snapshot

About

Decoy Therapeutics Inc. is a biotechnology company focused on developing novel therapies for immune-mediated diseases. The company's approach involves using decoy receptor technology to intercept and neutralize disease-causing proteins. Decoy Therapeutics is advancing a pipeline of drug candidates through preclinical and clinical development stages. The company operates in the competitive biopharmaceutical sector with focus on innovative treatment mechanisms.